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INTRODUCTION
Fibrosis is a pathologic process of tissue remodeling accom-
panied with an accumulation of extracellular matrix (ECM)
proteins. Several organs and tissues are affected by fibrosis such
as kidney, lung, liver, heart, vessel, peritoneum or skin. The
etiology of fibrosis is a tissue injury like inflammation, radi-
ation, wound etc., but still many cases are idiopathic. Even
though the pathogenesis of fibrosis is not fully understood yet,
it is caused by imbalance between the accumulation and the
degradation of ECM. Several factors, such as TGF- , connec-
tive tissue growth factor (CTGF), vascular endothelial growth
factor (VEGF), reactive oxygen intermediates, or matrix met-
alloproteinase and their inhibitors are involved in the regula-
tion of synthesis and degradation of ECM with complex net-
work according to the type of tissues or organs (1-8). At the
present time, fibrotic diseases of various organs in human are
treated with corticosteroids and cytotoxic drugs that have seri-
ous systemic adverse effects (9, 10).
Pirfenidone (PFD) is a recently developed drug and it is in-
tensively studied as a therapeutic agent for fibrosis of differ-
ent organs (11-23). There are several reports to examine the
ability of PFD on renal fibrosis. The researchers used diverse
animal models such as 5/6 nephrectomy rats, unilateral ureter-
al obstructed rats or rabbit, streptozotocin-diabetic rat or vana-
date-induced kidney fibrosis rats for the evaluation of the activ-
ity of PFD against fibrosis (16-19). The FGS/Kist mouse devel-
ops a progressive glomerulosclerosis genetically and revealed
characteristic morphology of focal glomerulosclerosis (24-28).
Therefore, it is regarded as a suitable animal model for the
study of human spontaneous progressive glomerulosclerosis
(24-28). Consequently, we employed FGS/Kist mouse to deter-
mine if PFD is effective in the preventing the spontaneous pro-
gressive glomerulosclerosis. The data presented in this paper
indicated that long-term intake of PFD reduced ongoing pro-
gress of renal fibrosis and improve renal function.
MATERIALS AND METHODS
Animals
FGS/Kist mice were offered by KIST (Korea Institute of
Science and Technology). The 6-weeks old male and female
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Pirfenidone Suppressed the Development of Glomerulosclerosis in the
FGS/Kist mouse
Pirfenidone (PFD) is a newly developed anti-fibrotic agent. We evaluated the effect
of PFD for the prevention of renal fibrosis using a spontaneous progressive glomeru-
losclerosis animal model, FGS/Kist mice. Male and female FGS/Kist mice were fed
a diet containing 0.5% PFD or the same control diet (CD) without PFD, for 1, 2, or
3-month periods. Body weight was monitored for the general effect of PFD on the
mice. Proteinuria and glomerular filtration rate (GFR) were evaluated for renal func-
tion. The sclerosis index was examined for the morphological changes. There were
no significant changes in body weight between the PFD and control groups in both
sexes. Proteinuria levels were low in all the PFD groups compared to the corre-
sponding CD groups. The sclerosis scores were also reduced in both sexes of
the 3-month PFD groups (p<0.05), and glomerular filtration rates were increased
in both sexes of the 3-month PFD groups compared to the CD groups. The treat-
ment of PFD for 1 or 2-month periods did not have statistic significances but the
treatment for 3 months had statistic significances in sclerosis and GFR compared
to CD groups. These results suggested that long-term administration of PFD sup-
pressed the progression of glomerulosclerosis and improved renal function of the
FGS/Kist mice.
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FGS/Kist mice were treated with PFD (Marnac Inc. Dallas,
TX, U.S.A.) for 1, 2, and 3- month periods with four heads
mice in each group. Powdered food mixed with PFD was freely
fed to the treatment groups, and the same food but without
PFD was fed to the control groups. The concentration of the
PFD was adjusted to 0.5% (w/w) in order to offer the dose at
500 mg/kg/day. All the animals were maintained under the
barrier system of an air-conditioned room at 22±2℃, 55±
5% relative humidity, and 12 hrs L/D cycle, and had free access
to tap water.
Measurement of Proteinuria and body weight
Proteinuria of each mouse was checked once a week with
Uriscan strips (Yeong-dong Pharmaceutical Corp., Seoul, Ko-
rea) and the body weight was also checked. Proteinuria was
scored as 1 point for  “+” , 1.5 point for  “+~++” , and 2 point
for  “++” so on, and the mean proteinuria of each group was
calculated. The median value of  “+” is 30 mg/dL,  “++” is
100 mg/dL,  “+++” is 300 mg/dL and  “++++” is 1,000
mg/dL.
Measurement of Glomerular filtration rate (GFR)
GFR was assessed by modified single injection of 99mTc-
DTPA method which was previously reported (29, 30). 99mTc-
DTPA (Du Pont-Nuclear, Boston, MA, U.S.A.) was admin-
istered to the peritoneum of the mice at the end date of the
treatment. Blood was collected by cardiac puncture 60 min
after the injection of radioisotope. Radioactivity in the plasma
was counted by  -counter (Cobra II, Packard, U.S.A.) and the
GFR was calculated with the following formula:
C=(V/t)×logn (P0/Pt)
where C is the GFR (mL/min) and V (mL) is the distribu-
tion volume of isotope calculated from body weight (29). P0
is the injected amount of radioactivity (cpm/mL) and Pt is the
amount of radioactivity in the plasma (cpm/mL) taken at 60
min after the injection.
Morphological investigations
Kidneys of the mice were removed immediately after tak-
ing the blood sample for GFR test. The left kidney was cut
into two pieces by sagittal section and fixed in 2.5% forma-
lin-Histochoice (Amresco, U.S.A.) for light microscopic exam-
ination. The right kidney was snap-frozen in liquid nitrozen
and kept in -80℃for in situ hybridization. The formalin fixed
tissues were embedded in paraffin and sectioned at 3  m, and
then stained with periodic acid-Schiff (PAS) for histological
examination by light microscopy. The severity of the glomeru-
losclerosis was estimated by the modified semi-quantitative
scoring system proposed by Raij et al. (31). Briefly, 100 glom-
eruli in each specimen were examined by microscope at a mag-
nification of ×400, and the severity of the lesion was graded
from 0 to 2 according to the percentage of glomerular involve-
ment. Thus, grade 0 represented normal glomerular; grade 1
lesion indicated mild or moderate segmental hyalinosis and/
or sclerosis involving less than 50% of the glomerular tuft;
grade 2, diffuse glomerulosclerosis with more than 50% of
the tuft involved. The sclerosis score in each animal was ex-
pressed as a mean of all scores obtained.
Statistical Analysis
The statistical significance was studied by Wilcoxon rank
sum test. Data are presented as mean±SEM of four mice. Sta-
tistical significance was set at p<0.05.
RESULTS
The Changes of Body Weight
The mean body weight of each period PFD group was com-
pared with that of each period of same sex CD group at the
beginning and the end of the treatment (Table 1). The last
body weights of male CD, male PFD, female CD, and female
PFD groups were 25.9, 25.7, 20.8, and 20.4 g in the 1-month
period groups, respectively. They were 32.5, 30.1. 25.9, and
25.5 g in the 2-month period groups and 29.1, 27.4, 25.7,
and 23.6 g in the 3-month period groups, respectively. There
were no significant differences in the mean body weight be-
tween the PFD groups and same sex CD groups (p>0.05) ex-
cept for the 3-month period female groups (p<0.05).
PFD Decreased Proteinuria
The mean proteinuria levels was checked as one of the mark-
ers of renal damage and compared at the beginning and at the
No. of <50% sclerosis glomeruli ×1+
No. of >50% sclerosis glomeruli ×2 Sclerosis score=
100 glomeruli
Tx* Periods
Male Female
Before Tx After Tx Before Tx After Tx
1 Month CD 20.5±1.4 25.9±1.9 16.7±0.8 20.7±1.4
PFD 23.1±1.7 25.7±1.6 16.6±0.9 20.4±1.3
2 Month CD 24.1±1.1 32.5±2.0 19.1±1.7 25.9±2.7
PFD 23.1±1.4 30.1±4.5 19.8±1.0 25.5±0.2
3 Month CD 19.3±1.2 29.1±4.5 16.0±0.6 25.7±1.6
PFD 18.2±0.5 27.4±2.3 18.4±0.5 23.6±1.5*
Mean body weights of each group were monitored at the beginning and
the end of treatment of pirfenidone. Each value represents mean±SEM
of four mice. Rate of gain weight of 3 month female PFD group was sig-
nificantly lower than those of 3 month female CD group (*p<0.05), Wilcox-
on rank sum test. *Tx: treatment.
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end of the experiment in each group (Table 2). In the 1-month
groups, the proteinuria scores increased at the end of the treat-
ment 62.5, 22.2, 63.6 and 47.3% in male CD, male PFD, fe-
male CD, and female PFD groups, respectively when com-
pared to before the treatment. They are also increased 45.4,
29.4, 33.3, and 42.8% in the 2-month and 45, 31.5, 33.3,
and 7.69% in the 3-month male CD, male PFD, female CD,
and female PFD groups, respectively. The proteinuria increase
was less in PFD groups compared with each period of the CD
groups (except the 2-month female groups) and were statis-
tically significant the 1-month male and 3-month female gro-
ups (p<0.05).
Effects of PFD on Renal Function
Renal function was evaluated by the GFR. In the 1-month
groups, the GFR of the PFD group was lower than the CD
group in both sexes, and the GFR was similar in all 2-month
groups (Fig. 1). The GFR was 23.8 and 23.5% higher in the
3-month PFD male and female groups compared to the 3-
month CD male and female groups, respectively, and was sta-
tistically signiticant in the 3-month female groups (p<0.05).
The GFR was increased in all of the 2-month period groups
(0.39-0.43 mL/min/g) compared to the 1-month period
groups (0.28-0.39 mL/min/g) but decreased in all of the 3-
month period groups (0.23-0.40 mL/min/g) compared to
the 2-month period groups.
PFD Suppressed Development of Sclerosis
The sclerosis scores were very low (between 0.03-0.06) in
all of the 1-month groups and there were no significant differ-
ences between PFD groups and control groups in both genders
(Fig. 2). The characteristic glomerular change of FGS/Kist mice
was sclerosis; segmental collapse of glomerular capillary tufts
and luminal obliteration with matrix protein. It started from
very small area of glomerulus of 1-month group and gradu-
ally involved in whole glomerulus, which was well demon-
strated in 3-month male CD group (Fig. 3A, C). The number
of sclerotic glomeruli was also increased by age. The tubular
atrophy and interstitial fibrosis as well as interstitial lympho-
cytic infiltration were also associated with similar degree of
glomerular sclerosis in CD groups (Fig. 3A). However, PFD
protected the development of glomerulosclerosis and tubu-
lointerstitial fibrosis significantly (Fig. 3B, D). The sclerosis
score increased according to get old in male CD groups, such
as 0.03, 0.41, and 1.04 in 1, 2, and 3-month groups, respec-
tively. But it was only 0.04, 0.21, 0.23 in corresponding male
PFD groups and there is a significant difference between the
3-month CD and PFD male groups (p<0.05) (Fig. 2). There
was no significant increase of sclerosis in the 2-month female
groups (0.05 and 0.09 in CD and PFD groups, respectively),
when compared to the 1- month groups (0.05 and 0.06 in CD
and PFD groups, respectively). In the 3-month female groups,
G
F
R
 
(
m
L
/
m
i
n
/
g
)
Treatment period (months)
male CD
male PFD
female CD
female PFD
0.6
0.5
0.4
0.3
0.2
0.1
0
123
Fig. 1. Effect of PFD on GFR. Glomerular filtration rates were mea-
sured as described in Materials and Methods. Each value repre-
sents mean±SEM of four mice. GFR of 3-month female PFD group
was significantly higher (p<0.05) than 3-month female CD group,
Wilcoxon signed rank test.
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Fig. 2. Effect of PFD on sclerosis. Sclerosis scores were measured
as described in Materials and Methods. Each value represents
mean±SEM of four mice. Sclerosis scores of 3-month month male
and female PFD groups were significantly lower than correspond-
ing 3-month CD groups (p<0.05), Wilcoxon rank sum test.
*
*
Tx* Periods
Male Female
Before Tx After Tx Before Tx After Tx
1 Month CD 1.1±0.3 3.0±0 1.0±0 2.8±0.5
PFD 1.8±0.3 2.5±0.6* 1.3±0.5 2.4±0.5
2 Month CD 1.5±0.6 2.8±0.5 1.3±0.5 1.9±0.6
PFD 1.5±0.6 2.1±0.6 1.0±0 1.8±0.5
3 Month CD 1.4±0.5 2.5±0.6 1.8±0.3 2.6±0.5
PFD 1.6±0.5 2.4±0.8 1.5±0.6 1.6±0.3*
Mean proteinuria scores of each group were monitored at the beginning
and the end of treatment of Pirfenidone. Each value represents mean±
SEM of four mice. The increasing rate of mean proteinuria was significant-
ly lower in 1-month male and 3-month female PFD groups than 1-month
male and 3-month female CD groups, respectively (*p<0.05), Wilcoxon
rank sum test. Tx: treatment.
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the sclerosis score increased to 0.28 in the CD group but it
was still 0.04 in the PFD group (p<0.05) (Fig. 2). Therefore,
PFD reduced sclerosis 78% in 3-month male and 84% in 3-
month female groups compared to corresponding CD groups
(p<0.05).
DISCUSSION
Renal fibrosis is a complication of kidney injury and can
contribute to renal failure regardless of its preceding disease.
It may develop not only as a result of nephrectomy, chronic
infection, obstruction of ureter, malignant hypertension, severe
diabetic condition, or intoxication of heavy metals but also
idiopathic. Several kinds of renal fibrosis animal models are
used for the evaluation of efficacy and mechanism of drugs or
to elucidate the mechanism of pathogenesis. Common meth-
ods to induce renal fibrosis are 5/6 nephrectomy, unilateral
ureteral obstruction, administration of streptozotocin, injec-
tion of vanadate, or administraion of puromycin (16-19, 32,
33). All of the above renal fibrosis models represent special
situations such as removed, obstructive, diabetic, inflamma-
Fig. 3. Morphologic changes of kidney tissue. (A, C) FGS/Kist mouse kidney of 3-month male CD group shows glomerulosclerosis and
tubulointerstitial injury pattern, segmental collapse of glomerular capillary tufts and luminal obliteration with matrix protein (A, PAS stain, ×40,
C, ×400). (B, D) These changes are significantly ameriolated in 3-month male PFD group (B, ×40, D, ×400).
A B
C Dtory or intoxicated kidney.
The FGS/Kist mouse, which originated from the FGS/Nga
mouse, develops a spontaneous progressive glomerulosclero-
sis (24-28). The FGS/Nga mouse was established from the F5
offspring of a cross-breeding of CBA/Nga and RFM/Nga mice
(24, 25). It is known that the two pairs of autosomal recessive
genes are involved in the disease of this animal (24). In the
previous reports, the FGS/Kist strain showed progression of
proteinuria and focal glomerulosclerosis with the aging (26,
27). Those findings resemble the focal glomerulosclerosis of
human and this animal is considered as a suitable animal model
for the idiopathic glomerulosclerosis (24-28).
Pirfenidone (PFD) is a broad spectrum anti-fibrotic agent
developed recently. There are many reports about the effec-
tiveness and mechanism of the PFD against several kinds of
fibrotic disease such as lung fibrosis, renal fibrosis, liver cir-
rhosis, sclerosing peritonitis etc. (11-23). We employed FGS/
Kist mice to evaluate the effectiveness of PFD on the spon-
taneous glomerulosclerosis.
As a parameter for general condition, we checked body we-
ight. The proteinuria levels were monitored and glomerular
filtration rates were evaluated for the renal function. During
the administration of PFD, there were no significant differences
on body weight between the CD and the PFD treatment gro-
ups in each treatment periods except in the 3-month female
groups (Table 1). This result suggested that the administra-
tion of PFD for 3 months might not cause significant toxicity
to FGS/Kist mice. In the beginning of the treatment (6 weeks-
old mice), the proteinuria levels were similar (scores were be-
tween 1-1.75) in all groups (Table 2). The level of proteinuria
had increased in all groups at the end of the experiment but
there was a tendency for less increases in the PFD groups (score
1.63-2.5) compared to the corresponding CD groups (score
1.88-3.0). The effectiveness of PFD against proteinuria, before
and after the treatment, was statistically valid (p<0.05) in the
3-months months male and female groups (Table 2).
Renal function was evaluated by GFR. The GRF was in-
creased in the 2-month groups compared to the 1-month gro-
ups and then decreased in 3-month groups when compared to
the 2-months groups (Fig. 1). It was considered that the increase
of the GFR in the 2-months groups might be due to growth
of the mice without severe disease, and the decrease of the
GFR in the 3-months groups was because of the progression
of the sclerosis. The GFR of the 2-months groups was similar
in all groups (0.41, 0.42, 0.39, and 0.43 mL/min/g in the male
CD, the male PFD, the female CD, and the female PFD groups,
respectively). The GFR of the 3-months groups decreased
42.1, 30.3, 16.5, and 6.67% in the male CD, male PFD, female
CD, and female PFD groups, respectively, when compared
with corresponding 2-months groups. The severity of fibrosis
was evaluated by sclerosis score. In all 1-month groups, there
was no significant sclerosis even though they had proteinuria
(Fig. 2, Table 2). The proteinuria probably preceded the mor-
phological change in the FGS/Kist mouse. Instead of CD gro-
up, in which the sclerosis scores had increased abruptly, the
sclerosis scores did not increase significantly in the 2 and 3-
months PFD male groups (Fig. 2). In female CD groups, there
was no significant sclerosis until the 2-months groups, and
then the score increased in the 3-months groups, but there
was no significant sclerosis in the PFD female groups of all
periods. Not only the glomerulosclerosis, tubulointerstitial
fibrosis also developed in FGS/Kist mice, but the treatment
of PFD also improved the tubulointerstitial fibrosis (Fig. 3).
Therefore, the treatment of PFD for 3 months improved renal
function and suppressed the development of sclerosis.
Accumulation of extracellular matrix (ECM) is the hallmark
in glomerulosclerosis and subsequently leads to end-stage renal
disease. It occurs as a result of an imbalance between synthesis
and degradation of matrix proteins. Therefore, balancing the
rate of synthesis and degradation of ECM is one of the targets
for the treatment of glomerulosclerosis. TGF- is known as
a most important cytokine in the pathogenesis of fibrosis.
TGF- regulates the turnover of ECM via several different
pathways. For example, TGF- stimulates the synthesis of
ECM, protease inhibitors, integrins, or reduces the synthesis
of ECM-degrading proteases (2). On the other hand, major
physiologic degradation of ECM is regulated by the matrix
metalloproteinases (MMPs) such as collagenases, gelatinases,
stromelysins, and membrane-type matrix metalloproteinases.
Stromelysin-1 (MMP-3), one of the MMPs, degrades ECM
and has a broad substrate specificity, including IV-collagen,
laminin, fibronectin, and proteoglycans (34). The catalytic
activity of MMPs is regulated at multiple levels including
transcription, secretion, activation, and inhibition. Inhibition
of MMPs activity is accomplished by the members of the tis-
sue inhibitors of the metalloproteinase (TIMP) family such as
TIMP-1, -2, -3 and -4. TIMP-1, -2 and -3 are present in the
kidney (6, 7). TIMP-1 is a glycoprotein produced by virtually
all mesenchymal tissues including intrinsic glomerular cells,
fibroblasts and inflammatory cells such as macrophages (6).
TIMP-1 inactivates stromelysin, interstitial collagenase and
the latent gelatinase. The importance of MMP-3 and TIMP-1
in the turnover of ECM has been reported in several models
or diseases of progressive renal scarring (3).
In the present study, we also observed mRNA expression
of TGF- , MMP-3 and TIMP-1 by northern blot to inves-
tigate the mechanism of anti-fibrotic action of PFD. TGF-
was decreased in PFD group compared to the CD and 2-month
male group showed statistical significance (data not shown).
TIMP-1 was all decreased in all male PFD groups but not sig-
nificant statistically (data not shown). However, MMP-3 was
detected only in 3 months groups and decreased in male PFD
group (data not shown). The induction of MMP-3 at 3-month
group was considered as a physiologic balance for the increase
of TIMP-1 and fibrosis. There was a tendency that TGF-
and TIMP-1 mRNA expressions were decreased in 2-month
and 3-month male PFD groups compared to the correspond-
ing male CD groups, but they were increased in female. There-
Pirfenidone Effects on FGS/Kist Mice 531fore, the effects of PFD on the mRNA expression of TGF- ,
TIMP-1 and MMP-3 showed some discrepancies between both
sexes. The disease of FGS/Kist is related with two autosomal
recessive genes, even though we do not know yet what kind
of genes they are (24). When we considered the following data
such as FGS/Kist mice are inbred mice (24), they have immune
complexes and retroviral envelop antigen in their kidney (25),
the morphology of renal disease of FGS/Kist mice resemble
the pathology of the kidney disease of human immunodefi-
ciency acquired disease (personal communication), there is a
possibility that the disease of FGS/Kist mice might be relat-
ed with endogenous retroviruses (ERV). Some diseases such
as rheumatoid arthritis, systemic lupus erythematosus, which
are known to related with ERV, have some gender preferences
(35-37). Therefore, if the disease of FGS/Kist mice was related
with ERV, there could be some differences in the development
of the disease in male and female. It is obvious that PFD im-
proves renal function and suppresses sclerosis in both sexes of
FGS/Kist mice, but we could not find the consistent molec-
ular mechanism of PFD in both sexes of FGS/Kist mice in the
transcriptional level. However, the mechanism of the fibrosis
is a very complicate network in vivo and involved several mo-
lecules in transcriptional, and post-transcriptional level, we
could not explain the mechanism of PFD in this study. There-
fore, further studies are needed to confirm the mechanism of
PFD in the prevention of glomerulosclerosis.
From the above data, we conclude that 1) the proteinuria
developed in young FGS/Kist mice and preceded fibrotic
changes, 2) the severity of the disease depends on both age and
gender (males showed a greater severity of disease), 3) long-
term (3 months) administration of pirfenidone improved renal
function and suppressed sclerosis in the FGS/Kist mice.
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